A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients

NCT07671378 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

CLL (Chronic Lymphocytic Leukemia)

Interventions

DRUG: Zanubrutinib and sonrotoclax

Sponsor

The First Affiliated Hospital with Nanjing Medical University